2.25
+2.74%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Guangxi Wuzhou Zhongheng Group Co
Its shares trade on Shanghai under the ticker 600252.SS. It has been listed since 30 November 2000. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.75bn and a net loss of CN¥357.1m. At that date it held total assets of CN¥10.07bn and shareholders' equity of CN¥5.37bn.
Guangxi Wuzhou Zhongheng Group Co., Ltd. engages in the pharmaceutical manufacturing, food production, and real estate development and management. The company is headquartered in Wuzhou, Guangxi. The company went IPO on 2000-11-30. The firm's pharmaceuticals include cardiovascular drugs, medicine for bruises, gynecology medication and other general drugs. The firm also provides Chinese herbal jelly products, Chinese herbal beverages and others. The firm is also engaged in the development of real estate, including the development and sales of commercial housings and stores. The firm mainly conducts its businesses within domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 30 Nov 2000
- Employees
- 3,355
- Website
- wz-zhongheng.com ↗
Leadership
Pay as last reported
- Mr. Jinhai YangChairman of the Board, since 2023
- Mr. Hui GeFinance DirectorCN¥217,500
- Mr. Hairun WangGeneral Counsel, Deputy General Manager, Secretary of the Board, Director, since 2022
- Mr. Ming ChenDeputy General Manager, since 2009CN¥1.6m
- Mr. Weimin PengDeputy General Manager, since 2003CN¥1.5m
- Mr. Tianjiao WangDeputy General Manager
- Mr. Xiangyong WangDeputy General ManagerCN¥1.0m
- Mr. Lin XiaoDeputy General ManagerCN¥1.1m
- Mr. Hu ChenDirector
- Ms. Shiyue XuDirector
- Mr. Daofeng ChenIndependent DirectorCN¥40,000
- Mr. Xingchu GongIndependent DirectorCN¥40,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 56
- Environment
- 87
- Social
- 63
- Governance
- 17
- Direct emissions (scope 1)
- 7,289.52 t
- Energy emissions (scope 2)
- 17,169.49 t
- Women in the workforce
- 55.77247%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Pharmaceuticals include cardiovascular drugs and gynecology medication in domestic market.
- Food production offers Chinese herbal jelly and beverages for health care segment.
- Real estate development focuses on commercial housing and store sales in Wuzhou.
Weaknesses
- Employees count of 3355 is lower than industry average for pharmaceuticals.
- Listed since 2000 lacks recent market expansion in overseas markets.
- Business description mentions domestic market focus without overseas growth strategy.
Opportunities
- Overseas markets present growth potential for pharmaceuticals and food products.
- Real estate development can expand into new commercial housing projects in Wuzhou.
- Pharmaceuticals segment can leverage cardiovascular drug demand in China.
Threats
- Competition in domestic pharmaceutical market affects pricing for cardiovascular drugs.
- Real estate development faces challenges from economic slowdown in Wuzhou.
- Food production segment must adapt to changing health care trends in China.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.